Short Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Expands By 95.2%

Vincerx Pharma, Inc. (NASDAQ:VINC) was the recipient of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 863,700 shares, a growth of 95.2% from the February 29th total of 442,400 shares. Currently, 6.4% of the shares of the company are sold short. Based on an average trading volume of 1,030,000 shares, the short-interest ratio is presently 0.8 days.

Vincerx Pharma Stock Up 18.4 %

NASDAQ VINC opened at $6.06 on Thursday. The stock’s 50 day moving average is $3.50 and its two-hundred day moving average is $1.82. Vincerx Pharma has a 1-year low of $0.61 and a 1-year high of $9.37.

Institutional Investors Weigh In On Vincerx Pharma

A number of institutional investors have recently added to or reduced their stakes in VINC. Susquehanna International Group LLP acquired a new position in shares of Vincerx Pharma in the 1st quarter worth approximately $28,000. Goldman Sachs Group Inc. boosted its holdings in shares of Vincerx Pharma by 21.3% in the 2nd quarter. Goldman Sachs Group Inc. now owns 36,126 shares of the company’s stock worth $48,000 after acquiring an additional 6,334 shares in the last quarter. Rhumbline Advisers bought a new position in Vincerx Pharma in the 1st quarter worth approximately $53,000. ExodusPoint Capital Management LP bought a new position in Vincerx Pharma in the 2nd quarter worth approximately $132,000. Finally, Walleye Capital LLC bought a new position in Vincerx Pharma in the 2nd quarter worth approximately $176,000. 44.02% of the stock is owned by institutional investors and hedge funds.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.